Debajit Sen Sharma joins as Group CFO of Paras healthcare

Debajit Sen Sharma is appointed as Group Chief financial officer of Paras healthcare today. He will take care of strategising companys […]

Udbhav Ganjoo Quits Ranbaxy, May Join Mylan

Udbhav Ganjoo, the global Head of Human Resources Ranbaxy Laboratories, has resigned from the company and may join multinational pharmaceutical […]

Sun Pharma hits record high

Shares of Sun Pharmaceutical Industries and Ranbaxy Laboratories are trading higher by 2 percent. Sun Pharma stock surged 2 percent […]

USFDA Withdrwas Sales Ban as Indian Pharma Companies Take Corrective Measures

A new recommendation has come in for the Indian drug companies. Most Indian drug companies that were penalised for violating […]

Glenmark tops the charts in US

US approve the sale of low cost medicines by Glenmark Pharmaceuticals this financial year by winning the bids against Sun Pharma, Ranbaxy Laboratories and Dr Reddy.

NEWS REVIEW

[This article was published in the June 2009 issue of the eHEALTH Magazine (https://www.ehealthonline.org)]

eHealth News

Ranbaxy starts phase III study of anti-malaria drug

Ranbaxy Laboratories announced that its new anti-malarial combination drug is now undergoing final stage of development. In its press-release, the company said that the drug is targeted at patients in developing countries with the aim of significantly improving upon the conventional options available for the treatment of P falciparum malaria.

Israel’s Teva pharma to invest INR 4,000 cr in India

Israel

CRAMS to global pharma companies, give good returns

The pharma sector may have underperformed in the Sensex , but companies providing contract research and manufacturing services (CRAMS) to global pharma companies have given good returns.

CRAMS to global pharma companies, give good returns

The pharma sector may have underperformed in the Sensex , but companies providing contract research and manufacturing services (CRAMS) to global pharma companies have given good returns.

Ranbaxy may dilute 60% in new R&D unit

Ranbaxy Laboratories may dilute up to 60% stake in its new research company, which will be formed by hiving off its R&D unit into a separate entity in 2008.

NEWS REVIEW – BUSINESS

[This article was published in the November 2007 issue of the eHEALTH Magazine (https://www.ehealthonline.org)]

News Review

Ranbaxy to make China a major sourcing hub

Pharmaceuticals major Ranbaxy Laboratories plans to make China its major sourcing hub for active pharmaceutical ingredient (API).